Navamedic ASA: Enters into long-term agreement for distribution of GoNitro®* in the Nordics
Oslo, November 20, 2017 - Navamedic ASA (OSE: NAVA), the Norwegian medtech and pharmaceutical products company, today announced it has entered into a preliminary long-term agreement with G. Pohl-Boskamp GmbH & Co. KG for the Nordic launch and commercialisation of GoNitro®*, a new nitroglycerin sublingual powder formulation for acute relief of an attack or prophylaxis of angina pectoris. "We are very pleased to announce a planned extension of our partnership with Pohl-Boskamp for distribution of the prescription medicine GoNitro (nitroglycerin) sublingual powder in the Nordic markets.